AU2019325486A1 - The use of alpha-2-adrenergic receptor agonists for improving vision - Google Patents
The use of alpha-2-adrenergic receptor agonists for improving vision Download PDFInfo
- Publication number
- AU2019325486A1 AU2019325486A1 AU2019325486A AU2019325486A AU2019325486A1 AU 2019325486 A1 AU2019325486 A1 AU 2019325486A1 AU 2019325486 A AU2019325486 A AU 2019325486A AU 2019325486 A AU2019325486 A AU 2019325486A AU 2019325486 A1 AU2019325486 A1 AU 2019325486A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- use according
- formula
- improvement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 | |
| US62/720,671 | 2018-08-21 | ||
| PCT/US2019/047305 WO2020041340A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019325486A1 true AU2019325486A1 (en) | 2021-03-25 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019325486A Abandoned AU2019325486A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20210205273A1 (https=) |
| EP (1) | EP3840750A1 (https=) |
| JP (1) | JP2021534217A (https=) |
| KR (1) | KR20210047323A (https=) |
| CN (1) | CN112823003A (https=) |
| AR (1) | AR115991A1 (https=) |
| AU (1) | AU2019325486A1 (https=) |
| BR (1) | BR112021003295A2 (https=) |
| CA (1) | CA3110318A1 (https=) |
| CL (1) | CL2021000440A1 (https=) |
| CO (1) | CO2021003460A2 (https=) |
| IL (1) | IL280990A (https=) |
| MX (1) | MX2021002112A (https=) |
| PH (1) | PH12021550372A1 (https=) |
| SG (1) | SG11202101730SA (https=) |
| TW (1) | TW202021584A (https=) |
| WO (1) | WO2020041340A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023514732A (ja) * | 2020-02-20 | 2023-04-07 | アラーガン、インコーポレイテッド | アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 |
| US12023276B2 (en) | 2021-02-24 | 2024-07-02 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| AU2024217271A1 (en) * | 2023-02-08 | 2025-09-18 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| EP3085358B1 (en) | 2010-01-22 | 2017-11-01 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| WO2012149381A1 (en) * | 2011-04-28 | 2012-11-01 | Alpha Synergy Development, Inc. | Compositions and methods for improving night vision |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| WO2014143754A2 (en) | 2013-03-15 | 2014-09-18 | Allergan, Inc. | Prostamide-containing intraocular implant |
| JP2016515583A (ja) | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． | オキュラー・インサートおよびその使用方法 |
| ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| CN103338483B (zh) * | 2013-07-24 | 2016-08-10 | 成都西加云杉科技有限公司 | 数据分流方法、数据分流设备及异构网络 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en not_active Abandoned
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en not_active Ceased
- 2019-08-20 TW TW108129699A patent/TW202021584A/zh unknown
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/zh active Pending
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/ko not_active Withdrawn
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/es unknown
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/ja active Pending
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en not_active Withdrawn
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/pt not_active IP Right Cessation
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-21 AR ARP190102374A patent/AR115991A1/es not_active Application Discontinuation
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/es unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/es unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
-
2024
- 2024-03-08 US US18/599,800 patent/US20240358682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020041340A1 (en) | 2020-02-27 |
| JP2021534217A (ja) | 2021-12-09 |
| BR112021003295A2 (pt) | 2021-05-18 |
| KR20210047323A (ko) | 2021-04-29 |
| CO2021003460A2 (es) | 2021-04-08 |
| AR115991A1 (es) | 2021-03-17 |
| EP3840750A1 (en) | 2021-06-30 |
| MX2021002112A (es) | 2021-07-16 |
| US20220288031A1 (en) | 2022-09-15 |
| SG11202101730SA (en) | 2021-03-30 |
| PH12021550372A1 (en) | 2021-11-29 |
| IL280990A (en) | 2021-04-29 |
| US20240358682A1 (en) | 2024-10-31 |
| US20210205273A1 (en) | 2021-07-08 |
| CN112823003A (zh) | 2021-05-18 |
| CA3110318A1 (en) | 2020-02-27 |
| CL2021000440A1 (es) | 2021-09-20 |
| TW202021584A (zh) | 2020-06-16 |
| US20220160623A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240358682A1 (en) | Use of alpha-2-adrenergic receptor agonists for improving vision | |
| Mester et al. | Functional outcomes after implantation of Tecnis ZM900 and Array SA40 multifocal intraocular lenses | |
| RU2657514C2 (ru) | Офтальмологический состав и способ для облегчения пресбиопии | |
| JP2025168426A (ja) | 眼科用医薬組成物及びそれに関する使用 | |
| US20240390330A1 (en) | Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes | |
| AU2016396661B2 (en) | Cross-linking agents and associated methods | |
| US11077053B2 (en) | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia | |
| US20240335425A1 (en) | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision | |
| Pepose et al. | Reversal of pharmacologically induced mydriasis with phentolamine ophthalmic solution | |
| HK40053072A (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| HK40107891A (en) | Cross-linking agents and associated methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |